Cargando…
Antioxidant mitoquinone suppresses benign prostatic hyperplasia by regulating the AR–NLRP3 pathway
Mitoquinone (MitoQ), a mitochondria-targeted antioxidant, has been used to treat several diseases. The present study aimed to investigate the therapeutic effects of MitoQ in benign prostatic hyperplasia (BPH) models and their underlying molecular mechanisms. In this study, we determined that MitoQ i...
Autores principales: | Jin, Bo-Ram, Lim, Chae-Young, Kim, Hyo-Jung, Lee, Minho, An, Hyo-Jin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10368918/ https://www.ncbi.nlm.nih.gov/pubmed/37454529 http://dx.doi.org/10.1016/j.redox.2023.102816 |
Ejemplares similares
-
6′-Sialyllactose Ameliorates In Vivo and In Vitro Benign Prostatic Hyperplasia by Regulating the E2F1/pRb–AR Pathway
por: Jin, Bo-Ram, et al.
Publicado: (2019) -
Baicalin alleviates benign prostate hyperplasia through androgen-dependent apoptosis
por: Jin, Bo-Ram, et al.
Publicado: (2020) -
Anti-Proliferative Effects of HBX-5 on Progression of Benign Prostatic Hyperplasia
por: Jin, Bo-Ram, et al.
Publicado: (2018) -
6-sialyllactose ameliorates dihydrotestosterone-induced benign prostatic hyperplasia through suppressing VEGF-mediated angiogenesis
por: Kim, Eun-Yeong, et al.
Publicado: (2019) -
Oral administration of berberine represses macrophage activation-associated benign prostatic hyperplasia: a pivotal involvement of the NF-κB
por: Jin, Bo-Ram, et al.
Publicado: (2021)